drugset / Trial / NCT04332744
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, randomized, two-arm, phase II clinical trial to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with metastatic hormone-naïve prostate cancer (mHNPC)
Timeline
- Start
- 2020-09-02
- Primary completion
- 2025-05-06
- Completion
- 2025-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talazoparib | Small molecule | 0.5 mg | Oral |
| Background | Enzalutamide | Other / unclassified | 160 mg | Oral |